117 related articles for article (PubMed ID: 7796839)
1. Treatment of amyotrophic lateral sclerosis using a gene therapy approach.
Aebischer P; Kato AC
Eur Neurol; 1995; 35(2):65-8. PubMed ID: 7796839
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.
Aebischer P; Pochon NA; Heyd B; Deglon N; Joseph JM; Zurn AD; Baetge EE; Hammang JP; Goddard M; Lysaght M; Kaplan F; Kato AC; Schluep M; Hirt L; Regli F; Porchet F; De Tribolet N
Hum Gene Ther; 1996 May; 7(7):851-60. PubMed ID: 8860837
[TBL] [Abstract][Full Text] [Related]
3. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse.
Sagot Y; Tan SA; Baetge E; Schmalbruch H; Kato AC; Aebischer P
Eur J Neurosci; 1995 Jun; 7(6):1313-22. PubMed ID: 7582105
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.
Aebischer P; Schluep M; Déglon N; Joseph JM; Hirt L; Heyd B; Goddard M; Hammang JP; Zurn AD; Kato AC; Regli F; Baetge EE
Nat Med; 1996 Jun; 2(6):696-9. PubMed ID: 8640564
[TBL] [Abstract][Full Text] [Related]
5. [Neurotrophic factor treatment in amyotrophic lateral sclerosis].
Tsuzaka K; Mitsumoto H
No To Shinkei; 1998 Jul; 50(7):625-30. PubMed ID: 9739520
[No Abstract] [Full Text] [Related]
6. A gene therapy approach for the treatment of amyotrophic lateral sclerosis and Parkinson's disease.
Zurn AD; Tseng JL; Déglon N; Joseph JM; Aebischer P
Adv Pharmacol; 1998; 42():929-31. PubMed ID: 9328050
[No Abstract] [Full Text] [Related]
7. Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF.
Tan SA; Déglon N; Zurn AD; Baetge EE; Bamber B; Kato AC; Aebischer P
Cell Transplant; 1996; 5(5):577-87. PubMed ID: 8889216
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells.
Zurn AD; Henry H; Schluep M; Aubert V; Winkel L; Eilers B; Bachmann C; Aebischer P
Cell Transplant; 2000; 9(4):471-84. PubMed ID: 11038064
[TBL] [Abstract][Full Text] [Related]
9. Encapsulated xenogeneic cells: delivering CNTF to motor neurons.
O'Brien C
Mol Med Today; 1996 Nov; 2(11):448-9. PubMed ID: 8947909
[No Abstract] [Full Text] [Related]
10. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
Penn RD; Kroin JS; York MM; Cedarbaum JM
Neurosurgery; 1997 Jan; 40(1):94-9; discussion 99-100. PubMed ID: 8971830
[TBL] [Abstract][Full Text] [Related]
11. [Neurotrophic factors. Therapeutic approach in neurodegenerative diseases].
Wasielewski S
Med Monatsschr Pharm; 1992 Apr; 15(4):98-9. PubMed ID: 1584114
[No Abstract] [Full Text] [Related]
12. Neurotrophic factors in the treatment of motor neuron disease and trauma.
DiStefano PS
Exp Neurol; 1993 Nov; 124(1):56-9. PubMed ID: 8282081
[No Abstract] [Full Text] [Related]
13. Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis.
Armon C; Brandstater ME; Peterson GW
Muscle Nerve; 1997 Apr; 20(4):499-501. PubMed ID: 9121509
[No Abstract] [Full Text] [Related]
14. Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts.
Déglon N; Heyd B; Tan SA; Joseph JM; Zurn AD; Aebischer P
Hum Gene Ther; 1996 Nov; 7(17):2135-46. PubMed ID: 8934227
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in the ciliary neurotrophic factor receptor alpha gene and familial amyotrophic lateral sclerosis.
Imura T; Shimohama S; Kawamata J; Kimura J
Ann Neurol; 1998 Feb; 43(2):275. PubMed ID: 9485075
[No Abstract] [Full Text] [Related]
16. When neurotrophic factors get on your nerves: therapy for neurodegenerative disorders.
Stahl SM
J Clin Psychiatry; 1998 Jun; 59(6):277-8. PubMed ID: 9671338
[No Abstract] [Full Text] [Related]
17. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts.
Sautter J; Tseng JL; Braguglia D; Aebischer P; Spenger C; Seiler RW; Widmer HR; Zurn AD
Exp Neurol; 1998 Jan; 149(1):230-6. PubMed ID: 9454632
[TBL] [Abstract][Full Text] [Related]
18. Use of growth factors in the treatment of motor neuron diseases.
Windebank AJ
Adv Neurol; 1995; 68():229-34. PubMed ID: 8787234
[No Abstract] [Full Text] [Related]
19. The use of trophic factors in degenerative motoneuron diseases.
Yan Q; Miller JA
Exp Neurol; 1993 Nov; 124(1):60-3. PubMed ID: 8282082
[No Abstract] [Full Text] [Related]
20. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy.
Acsadi G; Anguelov RA; Yang H; Toth G; Thomas R; Jani A; Wang Y; Ianakova E; Mohammad S; Lewis RA; Shy ME
Hum Gene Ther; 2002 Jun; 13(9):1047-59. PubMed ID: 12067438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
